Articles

Compugen catches a new checkpoint

Discovery of ILDR2 as a novel immune checkpoint and potential for autoimmune diseases published in back-to-back papers
Written byMel J. Yeates
| 4 min read

TEL AVIV, Israel—Compugen Ltd. announced in early February the publication of the discovery and validation of the ILDR2 protein as a novel immune checkpoint, and its use as an Fc fusion protein for the treatment of autoimmune diseases, in two peer-reviewed papers in The Journal of Immunology.

According to Dr. Zurit Levine, vice president of research and discovery at Compugen, “ILDR2 (CGEN-15001T) is a member of the immunoglobulin superfamily (IgSF), which was identified by Compugen’s computational discovery platform as a novel B7-like protein based on shared bioinformatic characteristics with known B7 members. Proteins of the B7 family play a pivotal role in regulating immune responses and have thus became attractive targets for development of novel drugs for cancer immunotherapy and autoimmune diseases.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.